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2000-15	MDGs	
From the 
MDGs to 
the SDGs 
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The Millennium Development Goals	
1.		Eradicate	extreme	poverty	and	hunger.	
2.		Achieve	universal	primary	educa@on.	
3.		Promote	gender	equality	and	empower	
						women.	
4.		Reduce	child	mortality.	
5.		Improve	maternal	health.		
6.		Combat	HIV/AIDS,	malaria,	and	other	
					diseases.	
7.		Ensure	environmental	sustainability.	
8.		Develop	a	global	partnership	for		
					development.		
Page  4 
xxx00.#####.ppt  6/28/17 9:14 PM 
Page  5 
xxx00.#####.ppt  6/28/17 9:14 PM 
 
 
 
The Global Burden of Disease Study	
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The Global Burden of Disease 2013	
Expanded	use	of	vaccines	
•  83%	reduc@on	in	measles	deaths	
•  82%	reduc@on	in	tetanus	deaths	
•  57%	reduc@on	in	diphtheria/pertussis	deaths	
•  45%	reduc@on	in	Hib	deaths		
	
Development	new	vaccines	
•  Pneumococcal	disease	(36%	reduc@on	in	
deaths)	
•  Rotavirus	(63%	reduc@on	in	deaths)	
	
2.5	million	childhood	lives	saved		
through	these	ini@a@ves	
Page  7 
xxx00.#####.ppt  6/28/17 9:14 PM 
 
 
 
Page  8 
xxx00.#####.ppt  6/28/17 9:14 PM 
 
 
 
Page  9 
xxx00.#####.ppt  6/28/17 9:14 PM 
 
 
 
•  Texas	ranks	at	the	boXom	of	fully	immunized	children	
•  45,000	Personal	Belief	Exemp@ons	in	Texas	
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The Millennium Development Goals	
1.		Eradicate	extreme	poverty	and	hunger.	
2.		Achieve	universal	primary	educa@on.	
3.		Promote	gender	equality	and	empower		
						women.	
4.		Reduce	child	mortality.	
5.		Improve	maternal	health.		
6.		Combat	HIV/AIDS,	malaria	
						and	other	diseases.	
7.		Ensure	environmental	sustainability.	
8.		Develop	a	global	partnership	for		
						development.		
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•  19	million	
lives	saved	
from	AIDS	
•  30%	
reduc@on	
in	Malaria	
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“Other Diseases” 
The Neglected Tropical Diseases 
•  13-14 tropical infections: 
- Highly prevalent among the poor 
- Endemic in rural areas of low-income 
countries 
- Ancient afflictions 
- Chronic 
- Disabling (growth delays, blindness or 
disfigurement) 
- Stigmatizing 
- Poverty promoting  
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Ascariasis 
Trichuriasis 
Hookworm Disease 
Schistosomiasis 
Dengue and other 
   arboviruses  
Food-borne 
   trematodiases 
Lymphatic Filariasis 
Onchocerciasis   
Chagas disease 
Leishmaniasis 
NEGLECTED	TROPICAL	DISEASES: 
14	
NTDs infect more than 1 BILLION of the world’s poorest people 
 
 
 
 
 Trachoma   
Cysticercosis   
Echinococcosis 
Hansen’s Disease 
Rabies    
African Trypanosomiasis 
Guinea worm 
Yaws 
Buruli ulcer 
Mycetoma 
Zika 
Ebola 
761.9 million 
463.7 million 
428.8 million 
252.2 million 
79.6 million 
 
71.1 million 
 
38.5 million 
15.5 million 
6.7 million 
3.9 million 
3.6 million 
1.9 million 
1.4 million 
514,200 
17,400 
10,700 
<1,000 
Not determined 
Not determined 
Not determined 
4 million 
2,800 
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“It’s	quite	a	problem	for	me	when	I	have	to	stand	at	
work	for	long	periods.”	
Lympha@c	Filariasis	(“Elephan@asis”)	
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NTDs and Girls & Women 
Female Genital Schistosomiasis 
Zimbabwe	
OR	=	3	increase	in	HIV/AIDS	
Kjetland	et	al.		AIDS	2006	
	
Tanzania	
OR	=	4	increase	in	HIV/AIDS	
Downs	et	al.	AJTMH	2011	
100	million	girls	&	
women	
	
Africa’s	most	common	
gynecologic	
condiEon?	
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Ascariasis, Trichuriasis, Hookworm, Schistosomiasis,  
LF, Onchocerciasis, Trachoma 
Hotez	PJ	et	al.		Lancet		2009	
The	BoHom	Billion	Suﬀers	from	MulEple	NTDs!			
Page  18 
xxx00.#####.ppt  6/28/17 9:14 PM 
NTD Scale up with the U.S. Government 
+ Drug Donations from  
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USAID	NTD	Program	
>450	million	People	Rx:	Elimina@on	of	some	NTDs	
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10	SIGNIFICANT	GAINS	
Lymphatic filariasis 
-52% (2005-15) 
 
Onchocerciasis 
-52% (1990-2013) 
 
Trachoma 
-65% (1990-2013) 
 
Ascariasis 
-20% (2005-2015) 
 
Yaws  
Not determined 
20	
Rabies (Canine) 
-53%  
(2005-2015) 
 
Cysticercosis 
-21%  
(2005-2015) 
 
Leprosy 
Dracunculiasis 
-99%  
(1990-2013) 
Other approaches WASH 
African 
trypanosomiasis 
-78%  
(2005-2015) 
Case detection + 
Rx + Vector 
control 
Mass Drug 
Administration 
(MDA) 
Elimination targets: 
LF 
Trachoma 
Yaws 
African trypanosomiasis 
Dracunculiasis 
Leprosy (Hansen’s Disease) 
Source: GBD 2015 and GBD 2013 
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9	MAJOR	SETBACKS	
Schistosomiasis 
+30%  
(1990-2013) 
 
Hookworm 
-5%  
(1990-2013) 
 
Trichuriasis 
-12%  
(1990-2013) 
21	
Food-borne 
Trematodiases 
+51%  
(1990-2013) 
Ebola 
+28,000%  
(2005-2015) 
 
Coronaviruses 
 
Other approaches WASH 
Leishmaniasis 
+174%  
(1990-2013) 
 
Chagas disease 
+22%  
(1990-2013) 
 
Dengue & 
Other Arbovirus 
Infections 
+610%  
(1990-2013) 
Case detection + 
Rx + Vector 
control 
Mass Drug 
Administration 
(MDA) 
Losing the Battle:  
Vector-borne Neglected Diseases 
 Arthropods 
 Snails 
Zoonotic Neglected Diseases 
 Viral Diseases 
Source: GBD 2015 and GBD 2013 
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Are we playing 
“global health whack-a-mole”? 
AIDS	
Malaria	
Some	NTDs	
Childhood	dz	
NTDs	V.2.0	
Vector-borne	NTDs	
Zoono@c	NTDs	
MDGs	
SDGs	
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Explosive Outbreaks in the Americas 
Zika	Path:	Explosive	Paciﬁc	Outbreaks	
Emergence	of	Dengue	in	the	New	
World	in	1980s,	1990s	
Emergence	of	Chikungunya	in	New	
World	in	2013	(Saint	Mar@n)	
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Dengue	
Malaria	
Chikungunya	 Schistoso
miasis	
WNV	
Opisthor
chiasis	
Emerging	Vector-
borne	Disease	in	
Southern	Europe	
EMERGING	VECTOR	BORNE	NEGLECTED	DISEASE	IN	SOUTHERN	EUROPE	
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The Anthropocene 
The	Anthropocene	is	a	proposed	epoch	
that	begins	when	human	ac@vi@es	started	
to	have	a	signiﬁcant	global	impact	on	
Earth's	geology	and	ecosystems.	
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Anthropocene forces promoting NTDs 
Poverty	
Deforesta@on	
Urbaniza@on	
and	Human	
Migra@ons	
Climate	
Change	
Conﬂict	and	
Poli@cal	
Destabiliza@on	
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POVERTY:  “Blue Marble Health” 
- Neglected 
diseases of the 
poor living amidst 
wealth 
- A new framework 
for global science 
policy and the 
poverty-related 
diseases 
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Blue Marble Health: 
 The poor living among the wealthy (G20 + Nigeria) 
Hotez	PJ	(2013)	NTDs	V.2.0:	“Blue	Marble	Health”—Neglected	Tropical	
Disease	Control	and	Elimina@on	in	a	Shioing	Health	Policy	Landscape.	PLoS	
Negl	Trop	Dis	7(11):	e2570.	doi:10.1371/journal.pntd.0002570	
hXp://www.plosntd.org/ar@cle/info:doi/10.1371/journal.pntd.0002570	
WHO	+	GBD	2013	
•  73-78%	Leprosy	
•  61-78%	Chagas	
•  60-61%	Dengue	
•  57-60%	TB	
•  45-67%	VL	
•  50-52%	Helminths	
	
•  STH	
•  Schistosomiasis	
•  Lympha@c	Filariasis	
•  Onchocerciasis	G20	+	Nigeria	=	54%	Popula@on	and	86%	Global	Economy	
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Chagas disease in Argentina, Brazil, Mexico 
•  Ranking By GDP 
- 1. Brazil 
- 2. Mexico 
- 3. Argentina 
•  Ranking By Chagas 
- 1. Argentina 1.5 million 
- 2. Brazil 1.2 million 
- 3. Mexico 0.9 million 
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Brazil and Blue Marble Health 
Poverty	&	Disease	NE	Brazil:		
Schistosomiasis,	Leishmaniasis,	Chagas,	Dengue	
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Zika Microcephaly cases in NE Brazil 
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Poverty in Northeastern Brazil 
Salvador	de	Bahia	Recife	
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Spread of Zika in the Americas 
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POVERTY	IN	TEXAS	
South	Texas	“Colonias”	Shaghayegh	Tajvidi.	
Fioh	Ward,	Houston	Texas		
Anna	Grove	
Poverty	in	Texas		
Hotez	PJ	(2017)	The	
Rise	of	Neglected	
Tropical	Diseases	in	
the	‘New	Texas’	
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Hotez PJ “Zika is Coming”  
The New York Times April 9, 2016 
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WAR & POLITICAL DESTABILIZATION:  Ebola	
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ISIS-Occupied Syria, Iraq, Libya 
Yemen	
Measles/Polio	
Leishmaniasis	
Schistosomiasis	
Brucellosis	
MERS	CoV	
Dengue	
Malaria/TB	
Rio	Valley	Fever	
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Vaccinating Against The 
Anthropocene’s NTDs 
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Coali@on	for	Epidemic	Preparedness	Innova@ons	(CEPI)	
•  Building	on	the	WHO	R&D	blueprint	
•  Need	for	improved	R&D	preparedness	
					for	diseases	of	epidemic	poten@al	
•  Priori@za@on	of	pathogens	
•  Iden@ﬁca@on	of	R&D	priori@es	
•  Explora@on	of	funding	models	for	R&D	
					preparedness	and	response	
	Nipah	
	Lassa	
	MERS	CoV	
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Sabin PDP Pipeline and Disease Portfolio	
• Built	
structure	
• Launched	
Hookworm	
Program	
2000	
to	
2004	
• Expanded	
Hookworm	
Program	
• Schisto	
Program	
• Relocated	to	
TMC	
2004	
to	
2011	
• Added	7	
addiEonal	
programs	
• Expansion	of	
capabiliEes	
2011	
to	
2015	
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Rino Rappuoli: Reverse Vaccinology 
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Reverse vaccinology as a ‘holy grail’ 
for complex eukaryotic organisms 
- Large genomes of similar 
complexity to human 
genome 
- Inadequacy of bacterial 
expression systems for 
eukaryotic antigens 
- Low throughput not high 
throughput 
- Deficiencies in animal 
models 
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Vaccine Targeting 
Hookworm and Schistosomiasis Co-Infections	
A	MULTIVALENT	
VACCINE	TARGETING		
HOOKWORM	+	SCHISTO	
membrane	
1 2 3 4 
C 
G 
C 
C C 
C 
G/A G/A 
E/Q 
E/Q 
G/A 
K 
G/A F/Y 
G 
C 
E/Q 
P 
W/F/Y 
EC-1	
EC-2	
Page  45 
xxx00.#####.ppt  6/28/17 9:14 PM 
Goals of Anti-schistosome Vaccine 
•  Worm burden reduction 
•  Egg reduction 
•  Reduced end-organ 
pathology 
•  Reduction in inflammation 
•  Reduction in anemia and 
malnutrition 
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Immunomics Approach: 
Schistosome protein microarrays 
Page  47 
xxx00.#####.ppt  6/28/17 9:14 PM 
Immune localization of Sm-TSP-2 
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Suppression of tsp-2 mRNA expression results 
in impaired tegument turnover in vitro	
Tran	et	al.	PLoS	Path	2010	
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Intestinal Schistosomiasis Vaccine 
The	Schistosome	Tetraspanins	
Entering phase 1 trials – Baylor VTEU 
Entering phase 1 trials – Baylor VTEU 
Page  50 
xxx00.#####.ppt  6/28/17 9:14 PM 
The Rise of Emerging + Neglected Diseases 
in the “New Texas” 
•  Leading TX NTDs 
- Toxocariasis  700,000 
- Trichomoniasis 450,000 
- Chagas disease 37,000 
- WNV 183-1,900 
- Intestinal protozoan 1,000 
- Cysticercosis 195-754 
- Murine Typhus >100 
- Dengue, Zika, Chik 
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Trypanocidal	therapy	with	
benznidazole	in	pa@ents	with	
established	Chagas’	
cardiomyopathy	signiﬁcantly	
reduced	serum	parasite	detec@on	
but	did	not	signiﬁcantly	reduce	
cardiac	clinical	deteriora@on	
through	5	years	of	follow-up.		
The	role	of	trypanocidal	therapy	in	pa@ents	
with	established	Chagas’	cardiomyopathy	is	
unproven.	
ORIGINAL	ARTICLE	
	
Randomized	Trial	of	Benznidazole	
for	Chronic	Chagas’	
Cardiomyopathy	
	
Carlos	A.	Morillo,	M.D.,	Jose	Antonio	Marin-
Neto,	M.D.,	Ph.D.,	Alvaro	Avezum,	M.D.,	
Ph.D.,	Sergio	Sosa-Estani,	M.D.,	Ph.D.,	
M.P.H.,	Anis	Rassi,	Jr.,	M.D.,	Ph.D.,	Fernando	
Rosas,	M.D.,	Erick	Villena,	M.D.,	Roberto	
Quiroz,	M.D.,	Rina	Bonilla,	M.D.,	Constança	
BriXo,	Ph.D.,	Felipe	Guhl,	M.Sc.,	Elsa	
Velazquez,	Ph.D.,	Laura	Bonilla,	M.Sc.,	
Brandi	Meeks,	M.Eng.,	Purnima	Rao-
Melacini,	M.Sc.,	Janice	Pogue,	Ph.D.,	
Antonio	MaXos,	M.Sc.,	Janis	Lazdins,	M.D.,	
Ph.D.,	Anis	Rassi,	M.D.,	Stuart	J.	Connolly,	
M.D.,	and	Salim	Yusuf,	M.D.,	Ph.D.,	for	the	
BENEFIT	Inves@gators*	
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52	
Tc24-		24kDa	Trypanosoma	Cruzi	
Flagellar	Calcium	Binding	Protein	
TLR4 agonist: 
P P 
E6020 
Candidate	An@gen	 Candidate	Adjuvant	
+	
Tc24	protein	combined	with	E6020	in	a	Stable	
Squalene	Emulsion	as	a	lead	candidate	vaccine	
Addi@onal	an@gens	also	under	evalua@on	and	development	
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•  Preclinical Efficacy: 
- Pilot studies were performed to evaluate efficacy of 
recombinant Tc24 combined with imiquimod or MPLA when 
used as a preventative vaccine 
•  Preliminary Results 
• Reduce parasitemia  
• Increase survival during acute phase 
• Antigen specific IgG2a 
• Antigen specific IFNγ 
• Reduced cardiac parasite burden 
53 
ADVANCES IN A THERAPEUTIC CHAGAS VACCINE INITIATIVE 
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Western Blot comparison of Tc24-WT (A), Tc24-C2 (B), and Tc24-C4 (C) purified proteins. Lanes 
1-3: Non-Reduced. Lane 4: SeeBlue Plus Molecular Weight Marker. Lanes 5-7 Reduced. Lanes 1,5: 
Sample before size-exclusion chromatography (SEC) 8 µg load. Lanes 2,6: Post SEC low load (3 
µg). Lanes 3,7: Post SEC high load (8 µg). Detection was performed using mouse polyclonal 
antibody against Tc24 expressed in Pichia pastoris as primary antibody diluted 1:2,500 in PBST and 
an alkaline phosphatase conjugated goat anti-mouse secondary antibody diluted 1:7,500 in PBST. 
Oligomer Formation: Solving the problem? 
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Structural comparison of Tc24 constructs. a) Circular Dichroism (CD). Far UV CD spectrum of different 
constructs of Tc24 were taken on a Jasco J-1500. All tested Tc24 protein have a virtual identical CD profile 
with overlapping spectra. Negative peaks at 222 nm and 208 nm and a positive peak at 193 nm indicate that 
Tc24 is an α-helical protein. b) Thermal melting profile of Tc24-WT and Tc24-C4 measured using Protein 
Thermal Shift™ kit (Life Technologies). 
Maintaining secondary/tertiary structures 
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Therapeutic Chagas Disease Vaccine 
Increased		Ag-speciﬁc	IFNγ	
Decreased	T.	cruzi	burden	
Decreased	Cardiac	ﬁbrosis	
Experimental	Chagas	disease	vaccine	improves	
Cardiac	Echocardiography	func@on	
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